Biostage, Inc. (BSTG)
Stock Price:
$2.70 USD
0.20 (8.00%)
Updated Aug 7, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
23.44M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-8.40M |
| Shares Out |
8.68M |
| EPS (ttm) |
-1.13 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 7, 2020 |
| Last Price |
$2.70 |
| Previous Close |
$2.50 |
| Change ($) |
0.20 |
| Change (%) |
8.00% |
| Day's Open |
2.90 |
| Day's Range |
2.70 - 2.90 |
| Day's Volume |
395 |
| 52-Week Range |
1.79 - 4.88 |
More Stats
| Market Cap |
23.44M |
| Enterprise Value |
22.75M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
8.68M |
| Float |
4.23M |
| EPS (basic) |
-1.13 |
| EPS (diluted) |
-1.13 |
| FCF / Share |
-0.73 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
121,658 |
| Short Ratio |
3.35 |
| Short % of Float |
6.77% |
| Beta |
-0.14 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
33.70 |
| Revenue |
n/a |
| Operating Income |
-8.73M |
| Net Income |
-8.40M |
| Free Cash Flow |
-6.04M |
| Net Cash |
690,000 |
| Net Cash / Share |
0.08 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-269.44% |
| ROE |
-848.16% |
| ROIC |
-3,146.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
60.0
Current: $2.70
High
60.0
Target: 60.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | - | - | - | 0.08 | 0.12 | 0.09 | 0.02 | - | - | - |
| Revenue Growth | - | - | - | -30.51% | 26.88% | 322.73% | - | - | - | - |
| Gross Profit | - | - | - | -0.03 | -0.02 | 0.05 | 0.01 | - | - | - |
| Operating Income | -8.87 | -7.84 | -11.47 | -12.13 | -11.70 | -11.06 | -8.82 | -6.71 | -3.75 | -1.35 |
| Net Income | -8.33 | -7.53 | -11.92 | -11.58 | -11.70 | -11.06 | -8.82 | -6.71 | -3.75 | -1.35 |
| Shares Outstanding | 6.90 | 4.46 | 1.80 | 0.80 | 0.56 | 0.39 | 0.39 | 0.39 | - | - |
| Earnings Per Share | -1.21 | -1.69 | -6.63 | -14.49 | -21.00 | -28.20 | -22.80 | -17.40 | - | - |
| Operating Cash Flow | -6.06 | -7.64 | -11.01 | -9.06 | -7.19 | -7.99 | -7.69 | -5.90 | -3.57 | -1.05 |
| Capital Expenditures | -0.13 | -0.07 | -0.14 | -0.30 | -0.18 | -1.16 | -0.30 | -0.31 | -0.21 | - |
| Free Cash Flow | -6.19 | -7.71 | -11.15 | -9.36 | -7.36 | -9.16 | -7.98 | -6.21 | -3.78 | -1.05 |
| Cash & Equivalents | 0.96 | 1.36 | 4.04 | 2.94 | 7.46 | 5.27 | 14.01 | 0.00 | 0.00 | 0.00 |
| Total Debt | 0.19 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 0.77 | 1.36 | 4.04 | 2.94 | 7.46 | 5.27 | 14.01 | 0.00 | 0.00 | 0.00 |
| Assets | 1.99 | 2.63 | 5.05 | 4.55 | 8.96 | 7.20 | 15.06 | 0.44 | 0.19 | - |
| Liabilities | 0.90 | 0.66 | 1.62 | 2.78 | 0.65 | 0.71 | 0.50 | 0.41 | 0.17 | - |
| Book Value | 1.09 | 1.97 | 3.42 | 1.77 | 8.30 | 6.49 | 14.57 | 0.03 | 0.02 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Biostage, Inc. |
| Country |
United States |
| Employees |
9 |
Stock Information
| Ticker Symbol |
BSTG |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
OTCMKTS: BSTG |
Description
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.